Genmab A/S vs Walgreens Boots Alliance, Inc.: SG&A Expense Trends

SG&A Expense Trends: A Tale of Two Companies

In the ever-evolving landscape of corporate finance, understanding the trends in Selling, General, and Administrative (SG&A) expenses is crucial. This chart provides a fascinating comparison between Genmab A/S and Walgreens Boots Alliance, Inc. over the past decade.

Genmab A/S: A Steady Climb

From 2014 to 2023, Genmab A/S has seen a remarkable increase in SG&A expenses, growing from approximately $80 million to nearly $3.3 billion. This represents a staggering 4,000% increase, reflecting the company's aggressive expansion and investment in administrative capabilities.

Walgreens Boots Alliance, Inc.: Consistent Leadership

In contrast, Walgreens Boots Alliance, Inc. has maintained a steady SG&A expense trend, hovering around $23 billion to $25 billion annually. This stability underscores the company's mature market position and efficient cost management strategies.

The data for 2024 is incomplete for Genmab A/S, highlighting the dynamic nature of financial reporting.